Engineered virus teams up with immune drugs to fight tough cancers
NCT ID NCT03647163
Summary
This early-stage trial is testing the safety and effectiveness of a modified virus (VSV-IFNβ-NIS) when given alongside standard immunotherapy drugs (like pembrolizumab or nivolumab/ipilimumab). It is for adults with specific advanced solid tumors—including non-small cell lung cancer, neuroendocrine carcinoma, and kidney cancer—that have stopped responding to other treatments. The main goals are to find the safest dose and see if the combination can shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio, 44195, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.